BeataHolkovaMD
Hematology • Richmond, VAAssistant Professor, Internal Medicine, Virginia Commonwealth University, Medical College of Virginia School of Medicine
Are you Dr. Holkova?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 44 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1250 E Marshall St
Internal Medicine
Richmond, VA 23298Phone+1 804-828-7999Fax+1 804-828-5941- Is this information wrong?
Summary
- Dr. Beata Holkova, MD is a hematologist in Richmond, Virginia. She is currently licensed to practice medicine in Virginia and Michigan. She is affiliated with VCU Medical Center, Bon Secours Rappahannock General Hospital, and University of Virginia Medical Center.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
University at BuffaloResidency, Internal Medicine, 2001 - 2004
Comenius UniversityClass of 1991
Certifications & Licensure
VA State Medical License 2008 - 2022
MI State Medical License 2004 - 2011
Clinical Trials
- Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2008 Jul 09
- Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Start of enrollment: 2008 Dec 15
- Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Start of enrollment: 2010 Apr 26
- Join now to see all
Publications & Presentations
PubMed
- 21 citationsBelantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.Ajay K. Nooka, Katja Weisel, Niels W.C.J. van de Donk, David Routledge, Paula Rodriguez Otero, Kevin W. Song, Hang Quach, Natalie S. Callander, Monique C. Minnema, Suz...> ;Future Oncology. 2021 Mar 8
- 3 citationsPhase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome.Beata Holkova, Danielle Shafer, Victor Yazbeck, Sandeep S. Dave, Prithviraj Bose, Mary Beth Tombes, Ellen Shrader, Wen Wan, Dipankar Bandyopadhyay, Caryn Weir, Elizabe...> ;Leukemia & Lymphoma. 2021 Apr 16
- 1 citationsCorrection: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occurandand proceed through multiple mechanisms.Tri Nguyen, Rebecca Parker, Elisa Hawkins, Beata Holkova, Victor Yazbeck, Akhil Kolluri, Maciej Kmieciak, Mohamed Rahmani, Steven Grant> ;Oncotarget. 2019 Sep 3
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- Bon Secours Rappahannock General HospitalKilmarnock, Virginia
University of Virginia Medical CenterCharlottesville, Virginia
VCU Medical CenterRichmond, Virginia
